Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

REPL

Replimune Group Inc

Feb 06 • 04:00PM ET

7.75

+0.82 11.83 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX FATE SGMO KPTI ALVR PGEN ADAP ANIX ENTX

| Held by: VTI XBI IWM VXF IWN IBB VTWO FESM SCHA DFAS

Index	RUT	P/E	-	EPS (ttm)	-3.58	Insider Own	8.91%	Shs Outstand	79.63M	Perf Week	10.24%
Market Cap	639.94M	Forward P/E	-	EPS next Y	-2.08	Insider Trans	-0.47%	Shs Float	75.21M	Perf Month	-13.12%
Enterprise Value	447.15M	PEG	-	EPS next Q	-0.73	Inst Own	95.26%	Short Float	19.14%	Perf Quarter	-9.67%
Income	-314.85M	P/S	-	EPS this Y	-3.08%	Inst Trans	-3.86%	Short Ratio	8.96	Perf Half Y	41.42%
Sales	0.00M	P/B	2.93	EPS next Y	34.32%	ROA	-67.19%	Short Interest	14.40M	Perf YTD	-20.27%
Book/sh	2.64	P/C	2.38	EPS next 5Y	24.76%	ROE	-90.88%	52W High	14.80 -47.62%	Perf Year	-45.61%
Cash/sh	3.26	P/FCF	-	EPS past 3/5Y	-10.73% -14.85%	ROIC	-111.33%	52W Low	2.68 189.18%	Perf 3Y	-72.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.73% 6.63%	Perf 5Y	-80.26%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-13.96%	Oper. Margin	-	ATR (14)	0.51	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.60	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.01	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	5.60	EPS Q/Q	3.16%	SMA20	4.02%	Beta	0.74	Target Price	12.86
Payout	-	Debt/Eq	0.36	Sales Q/Q	-	SMA50	-12.21%	Rel Volume	1.06	Prev Close	6.93
Employees	479	LT Debt/Eq	0.34	Earnings	Feb 03 BMO	SMA200	-1.21%	Avg Volume	1.61M	Price	7.75
IPO	Jul 20, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.89% 39.99%	Trades		Volume	1,698,404	Change	11.83%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-25	Upgrade	BMO Capital Markets	Underperform → Market Perform	$11
Oct-27-25	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Oct-20-25	Upgrade	Wedbush	Neutral → Outperform	$18
Oct-20-25	Upgrade	Piper Sandler	Neutral → Overweight	$13
Oct-20-25	Upgrade	Leerink Partners	Market Perform → Outperform	$13
Oct-20-25	Upgrade	JP Morgan	Underweight → Neutral
Sep-19-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jul-23-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-23-25	Downgrade	BMO Capital Markets	Outperform → Underperform	$2
Jul-23-25	Downgrade	Barclays	Overweight → Equal Weight	$3
Jul-22-25	Downgrade	Wedbush	Outperform → Neutral	$4
Jul-22-25	Downgrade	Piper Sandler	Overweight → Neutral	$3
Jul-22-25	Downgrade	Leerink Partners	Outperform → Market Perform	$3
Jul-22-25	Downgrade	JP Morgan	Overweight → Neutral	$9
Jun-20-25	Initiated	Cantor Fitzgerald	Overweight
Aug-28-24	Initiated	ROTH MKM	Buy	$17
Apr-17-23	Resumed	Piper Sandler	Overweight	$44
Nov-19-21	Initiated	Piper Sandler	Overweight	$52
Oct-15-21	Resumed	BTIG Research	Buy	$60

Show Previous Ratings

Feb-03-26 08:00AM	Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +5.81%
Dec-31-25 02:42PM	Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months (Zacks)
Dec-18-25 08:00AM	Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-25 04:45PM	Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) (GlobeNewswire)
Nov-06-25 08:00AM	Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
05:47PM	Loading…
Oct-22-25 05:47PM	The Best AI for Picking Stocks, Ranked by Performance (MarketBeat)
Oct-20-25 04:10PM	Why Replimune Stock Was Soaring Today (Motley Fool) +98.78% -9.45%
07:00AM	Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma (GlobeNewswire)
Oct-19-25 08:00AM	Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 (GlobeNewswire)
Sep-24-25 11:06AM	REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug (Zacks)
Sep-22-25 05:35AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (PR Newswire)
Sep-19-25 04:08PM	Why Replimune Stock Was Tumbling Again Today (Motley Fool) -6.79%
10:12AM	Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment 'Uncertain' (Insider Monkey)
09:39AM	Intel downgraded, Tesla upgraded: Wall Street's top analyst calls (The Fly)
Sep-18-25 06:59PM	Why Replimune Stock Plummeted by Almost 40% Today (Motley Fool) -39.40%
09:15AM	Loading…
09:15AM	Replimune Provides Update Following Type A Meeting with FDA (GlobeNewswire)
05:48AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (PR Newswire)
Sep-12-25 04:42PM	Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025 - Contact Levi & Korsinsky (Newsfile)
Sep-04-25 12:56PM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (Business Wire)
09:30AM	Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman (PR Newswire)
Sep-03-25 04:18PM	Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman (PR Newswire)
Sep-02-25 08:00AM	Replimune Announces Type A Meeting Scheduled with FDA (GlobeNewswire) +9.26%
Aug-28-25 08:12AM	Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman (Newsfile)
Aug-26-25 08:46AM	Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL (PR Newswire)
Aug-25-25 09:31AM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile)
Aug-20-25 05:04PM	Investors in Replimune Group, Inc. (REPL): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile) +6.67%
Aug-14-25 04:19PM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile) +5.11%
Aug-13-25 03:40PM	Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025 - Contact Levi & Korsinsky (Newsfile)
Aug-12-25 09:00AM	Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REPL (PR Newswire) +5.21%
Aug-11-25 11:01AM	Controversial FDA regulator back 12 days after resigning (Quartz) -5.67%
08:00AM	Loading…
Aug-07-25 08:00AM	Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 08:45AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL (PR Newswire) +10.68%
Aug-04-25 09:52AM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile) -24.87%
Jul-30-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +101.33%
Jul-23-25 03:46PM	REPL STOCK LOSS: BFA Law Notifies Replimune Group, Inc. Investors to Contact the Firm after Stock Drops 75% on FDA Response Letter (Newsfile) +18.89%
Jul-22-25 04:07PM	Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock (Investor's Business Daily) -77.24%
11:05AM	Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment (Barrons.com)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
10:05AM	FDA Rejects Replimunes Skin Cancer Treatment, Shares Sink (Bloomberg)
07:00AM	Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma (GlobeNewswire)
Jul-11-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.46%
Jun-01-25 10:00AM	Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-29-25 08:00AM	Replimune to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) +11.15%
May-23-25 03:03AM	Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
12:02AM	Q4 2025 Replimune Group Inc Earnings Call (Thomson Reuters StreetEvents)
May-22-25 07:00AM	Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-16-25 08:00AM	Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day (GlobeNewswire) +8.58%
May-09-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 03:26PM	Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma (Seeking Alpha)
Apr-27-25 09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
Apr-11-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.21%
Mar-07-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-25 08:00AM	Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.32%
Feb-07-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.88%
Jan-23-25 07:06AM	Replimune price target raised to $21 from $17 at H.C. Wainwright (TipRanks) +5.61%
Jan-21-25 01:01PM	Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy (GuruFocus.com) +16.86%
08:00AM	Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma (GlobeNewswire)
Jan-10-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-25 08:00AM	Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials (GlobeNewswire)
Dec-23-24 08:00AM	Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-25-24 11:55PM	Replimune Announces Pricing of Upsized Public Offering (GlobeNewswire) -11.19% +8.45%
07:09AM	Replimune Announces Proposed Public Offering (GlobeNewswire)
Nov-22-24 04:00PM	S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results (Benzinga) +35.11%
05:48AM	Replimune's stock surges 19% after-hours on FDA BLA submission (Investing.com)
Nov-21-24 04:05PM	Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway (GlobeNewswire)
Nov-12-24 08:00AM	Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-24 01:00PM	Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) (GlobeNewswire)
Nov-08-24 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-24 09:15AM	Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Oct-09-24 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
Oct-07-24 09:11PM	Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings (GuruFocus.com)
Oct-01-24 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.58%
Sep-15-24 09:45AM	Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-09-24 08:00AM	Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 (GlobeNewswire)
Sep-05-24 08:00AM	Stockholders Vote to Elect Madhavan Balachandran to Board of Directors (GlobeNewswire)
Aug-22-24 08:00AM	Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-14-24 04:33PM	Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy (Pharmaceutical Technology)
Aug-13-24 08:00AM	Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma (GlobeNewswire)
Aug-08-24 08:00AM	Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-30-24 04:01PM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Jun-13-24 08:30AM	Replimune Announces $100 Million Private Placement Financing (GlobeNewswire) +7.26%
Jun-07-24 09:03AM	Replimune (REPL) Gains on Positive Data From Melanoma Study (Zacks) +11.11%
08:00AM	Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-06-24 12:16PM	Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? (Benzinga) +27.88%
07:00AM	Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma (GlobeNewswire)
Jun-03-24 08:00AM	Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-23-24 05:00PM	Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.77%
May-16-24 01:53PM	REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024 (InvestorPlace)
08:00AM	Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-07-24 05:00PM	Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Apr-04-24 08:00AM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-26-24 07:30AM	Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions (GlobeNewswire)
Mar-11-24 09:55AM	How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17% (Zacks)
Mar-08-24 12:00PM	What Makes Replimune Group, Inc. (REPL) a New Buy Stock (Zacks)
Mar-06-24 08:00AM	Replimune to Present at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-05-24 08:00AM	Replimune to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Feb-23-24 09:55AM	Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High? (Zacks)
Feb-08-24 08:42AM	Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway (GuruFocus.com)

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dhingra Kapil	Director	Dec 09 '25	Option Exercise	1.75	3,169	5,546	3,169	Dec 11 04:30 PM
Dhingra Kapil	Director	Dec 09 '25	Sale	10.40	3,169	32,958	0	Dec 11 04:30 PM
Kapil Dhingra	Director	Dec 09 '25	Proposed Sale	10.38	3,164	32,842		Dec 09 04:00 PM
Patel Sushil	Chief Executive Officer	Dec 02 '25	Sale	11.13	10,000	111,300	333,576	Dec 04 04:30 PM
Sushil Patel	Chief Strategy Officer	Dec 02 '25	Proposed Sale	11.13	10,000	111,303		Dec 02 04:11 PM
Sarchi Christopher	Chief Commercial Officer	Nov 17 '25	Sale	9.10	5,208	47,393	123,088	Nov 19 04:31 PM
Xynos Konstantinos	Chief Medical Officer	Nov 17 '25	Sale	9.10	7,248	65,957	139,685	Nov 19 04:30 PM
Hill Emily Luisa	Chief Financial Officer	Aug 15 '25	Sale	5.37	9,154	49,157	134,368	Aug 19 08:30 PM
Astley-Sparke Philip	Director	May 20 '25	Sale	8.06	32,279	260,169	1,405,071	May 22 09:47 PM
Xynos Konstantinos	Chief Medical Officer	May 20 '25	Sale	8.06	7,952	64,093	146,933	May 22 09:46 PM
Schwendenman Andrew	Chief Accounting Officer	May 20 '25	Sale	8.05	3,287	26,460	68,284	May 22 09:45 PM
Patel Sushil	Chief Executive Officer	May 20 '25	Sale	8.06	25,105	202,346	343,576	May 22 09:44 PM
Hill Emily Luisa	Chief Financial Officer	May 20 '25	Sale	8.05	2,535	20,407	143,522	May 22 09:44 PM
Sarchi Christopher	Chief Commercial Officer	May 20 '25	Sale	8.05	3,749	30,179	128,296	May 22 09:42 PM

Open in Screener

PTCT

PTC Therapeutics Inc

Feb 06 • 04:00PM ET

74.68

+2.32 3.21 %

Healthcare • Biotechnology • USA • NASD

PTCT PTC Therapeutics Inc daily Stock Chart

Peers: SRPT ALNY BIIB VRTX IONS RARE EXEL ARWR BLUE VYGR

| Held by: IJR VTI VB IWM XBI VBK VXF SPSM IJT IBB

Index	RUT	P/E	8.73	EPS (ttm)	8.56	Insider Own	4.10%	Shs Outstand	79.93M	Perf Week	-1.13%
Market Cap	6.00B	Forward P/E	-	EPS next Y	-1.07	Insider Trans	-14.25%	Shs Float	76.99M	Perf Month	-3.31%
Enterprise Value	4.72B	PEG	-	EPS next Q	0.10	Inst Own	105.42%	Short Float	13.37%	Perf Quarter	4.05%
Income	751.72M	P/S	3.37	EPS this Y	303.69%	Inst Trans	12.65%	Short Ratio	6.41	Perf Half Y	48.29%
Sales	1.78B	P/B	-	EPS next Y	-111.11%	ROA	33.51%	Short Interest	10.29M	Perf YTD	-1.69%
Book/sh	-1.95	P/C	3.55	EPS next 5Y	-	ROE	-	52W High	87.50 -14.65%	Perf Year	49.39%
Cash/sh	21.02	P/FCF	8.50	EPS past 3/5Y	14.01% -2.04%	ROIC	-	52W Low	35.95 107.73%	Perf 3Y	57.65%
Dividend Est.	-	EV/EBITDA	4.94	Sales past 3/5Y	14.42% 21.32%	Gross Margin	95.78%	Volatility	4.10% 4.53%	Perf 5Y	31.50%
Dividend TTM	-	EV/Sales	2.65	EPS Y/Y TTM	261.84%	Oper. Margin	51.84%	ATR (14)	3.04	Perf 10Y	224.27%
Dividend Ex-Date	-	Quick Ratio	2.26	Sales Y/Y TTM	97.54%	Profit Margin	42.25%	RSI (14)	47.57	Recom	1.93
Dividend Gr. 3/5Y	- -	Current Ratio	2.32	EPS Q/Q	114.06%	SMA20	-0.82%	Beta	0.50	Target Price	88.50
Payout	-	Debt/Eq	-	Sales Q/Q	7.23%	SMA50	-2.57%	Rel Volume	0.65	Prev Close	72.36
Employees	939	LT Debt/Eq	-	Earnings	Feb 19 AMC	SMA200	23.01%	Avg Volume	1.60M	Price	74.68
IPO	Jun 20, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	117.65% 22.04%	Trades		Volume	1,039,046	Change	3.21%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$119
Dec-01-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$91
Oct-20-25	Initiated	Wells Fargo	Overweight	$73
Jun-17-25	Initiated	Truist	Buy	$80
May-09-25	Upgrade	BofA Securities	Neutral → Buy	$68
May-07-25	Upgrade	Citigroup	Sell → Neutral	$40
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral	$41 → $55
Mar-07-25	Initiated	Scotiabank	Sector Perform	$55
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$45 → $67
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$39 → $63
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform	$44
Aug-26-24	Resumed	UBS	Buy	$47
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Dec-08-23	Initiated	Wells Fargo	Overweight	$37
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform	$165
Oct-27-23	Downgrade	Citigroup	Neutral → Sell	$29 → $17
Oct-06-23	Downgrade	Truist	Buy → Hold	$45 → $25
Sep-18-23	Downgrade	Citigroup	Buy → Neutral	$55 → $28

Show Previous Ratings

Feb-05-26 08:00AM	PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 (PR Newswire)
Jan-27-26 08:21AM	Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock? (Zacks)
Jan-26-26 09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
Jan-22-26 03:22AM	Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves (Insider Monkey)
Jan-12-26 08:30AM	PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference (PR Newswire)
04:30PM	Loading…
Jan-08-26 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-22-25 07:00AM	PTC Therapeutics Announces Approval of Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan (PR Newswire)
Dec-19-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.34%
Dec-18-25 08:00AM	PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.90%
09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-24-25 06:06PM	SanDisk stock surges after S&P 500 inclusion announcement (Investing.com)
06:01PM	Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600 (PR Newswire)
Nov-20-25 08:00AM	PTC Therapeutics to Host R&D Day (PR Newswire)
Nov-05-25 12:02AM	PTC Therapeutics Inc (PTCT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +5.98%
06:00PM	Loading…
Nov-04-25 06:00PM	Compared to Estimates, PTC Therapeutics (PTCT) Q3 Earnings: A Look at Key Metrics (Zacks)
05:25PM	PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates (Zacks)
04:21PM	PTC Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 07:24AM	What To Expect From PTC Therapeutics Inc (PTCT) Q3 2025 Earnings (GuruFocus.com)
Oct-31-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Oct-30-25 05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
Oct-29-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 12:24PM	Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76 (Insider Monkey)
10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-27-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-21-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results (PR Newswire)
Oct-10-25 11:55AM	Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? (Zacks)
Oct-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-11-25 11:15AM	PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU (Insider Monkey)
08:35AM	Loading…
Sep-05-25 08:35AM	Here's Why Shares in PTC Therapeutics Soared This Week (Motley Fool)
Sep-03-25 02:03PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily) +5.95%
Aug-29-25 04:52AM	PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich's Ataxia (Insider Monkey)
Aug-21-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-20-25 10:40AM	RBC says PTC Therapeutics CRL may signal difficulty for Biohaven (TipRanks)
10:35AM	PTC Therapeutics CRL expected, focus moves to Sephience, says RBC Capital (TipRanks)
Aug-19-25 08:00AM	PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA (PR Newswire)
07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive)
Aug-07-25 06:00PM	PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -9.89%
05:25PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:25PM	PTC Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-30-25 10:01AM	PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
08:00AM	Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE (sepiapterin) (PR Newswire)
Jul-28-25 04:19PM	PTC Therapeutics Announces FDA Approval of Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire) +11.16%
Jul-22-25 10:50AM	Phase II and Phase III Catalyst Monitor: Q3 2025 Outlook Report - Upcoming FDA Decisions Drive Momentum in Biopharma with Key Catalysts Across GHD, PKU, Presbyopia, and Wet AMD Treatments (GlobeNewswire)
06:54AM	Leigh Syndrome Market Research Report 2025-2035 \| Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics (GlobeNewswire)
Jul-21-25 04:30PM	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results (PR Newswire)
Jul-09-25 09:36AM	Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength? (Zacks)
Jun-23-25 07:00AM	Sephience (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Jun-19-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-06-25 12:00PM	All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy (Zacks)
May-10-25 10:35AM	PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw's Small-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 05:02AM	PTC Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +12.63%
03:20AM	PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-25 11:19PM	PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript (Seeking Alpha) -10.97%
04:01PM	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (PR Newswire)
11:03AM	PTC Therapeutics price target lowered to $57 from $65 at RBC Capital (TipRanks)
May-05-25 04:54PM	Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? (Benzinga) -18.62%
09:29AM	Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result (GuruFocus.com)
08:22AM	PTC stock slides on new data for Huntingtons drug (BioPharma Dive)
07:00AM	PTC518 PIVOT-HD Study Achieves Primary Endpoint (PR Newswire)
May-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-25-25 09:00AM	PTC Therapeutics Receives Positive CHMP Opinion for Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Apr-24-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Apr-21-25 07:30AM	uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold (Seeking Alpha)
01:56AM	uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 (Seeking Alpha)
Apr-17-25 10:01AM	PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results (PR Newswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -8.56%
Mar-28-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.05%
09:00AM	PTC Therapeutics Provides Regulatory Update on Translarna (ataluren) in Europe (PR Newswire)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-20-25 08:00AM	PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies (PR Newswire)
Feb-28-25 11:41AM	Q4 2024 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.27%
02:35AM	PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... (GuruFocus.com)
Feb-27-25 05:30PM	PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:17PM	PTC Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-26-25 07:21AM	PTC Therapeutics Inc (PTCT) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-25 09:16AM	Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-20-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	PTC Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-19-25 07:00AM	PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia (PR Newswire)
Feb-13-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-04-25 08:21AM	PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald (TipRanks)
05:01AM	PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? (Zacks)
Feb-03-25 03:07PM	Why PTC Therapeutics (PTCT) Stock Is Rallying Today (Insider Monkey) +9.00%
Jan-13-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.09%
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and RandD Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-23-24 08:00AM	PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-24 08:00AM	PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia (PR Newswire)
Dec-17-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 08 '26	Sale	76.45	1,034	79,049	72,693	Jan 12 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 08 '26	Sale	76.50	4,602	352,057	82,887	Jan 12 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 09 '26	Sale	77.41	1,722	133,300	81,165	Jan 12 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 12 '26	Sale	78.70	1,024	80,589	80,141	Jan 12 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 08 '26	Sale	76.45	2,514	192,195	394,453	Jan 12 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 08 '26	Sale	76.45	866	66,206	92,428	Jan 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 08 '26	Sale	76.56	4,033	308,760	113,626	Jan 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 09 '26	Sale	77.93	2,314	180,320	111,312	Jan 12 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '26	Sale	76.45	881	67,352	115,196	Jan 12 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '26	Sale	76.45	59	4,511	6,791	Jan 12 05:20 PM
Boulding Mark Elliott	Officer	Jan 09 '26	Proposed Sale	77.92	2,314	180,314		Jan 09 04:11 PM
Pauwels Eric	Officer	Jan 09 '26	Proposed Sale	77.89	2,746	213,889		Jan 09 04:09 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 06 '26	Sale	76.95	1,381	106,268	74,962	Jan 08 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 07 '26	Sale	77.45	1,235	95,651	73,727	Jan 08 05:20 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Jan 06 '26	Sale	76.95	2,139	164,596	90,310	Jan 08 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 06 '26	Sale	76.95	1,789	137,664	88,841	Jan 08 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 07 '26	Sale	77.48	1,352	104,753	87,489	Jan 08 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 06 '26	Sale	76.95	5,149	396,216	399,983	Jan 08 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 07 '26	Sale	77.48	3,016	233,680	396,967	Jan 08 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 06 '26	Sale	76.95	1,340	103,113	93,936	Jan 08 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 07 '26	Sale	77.48	642	49,742	93,294	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '26	Option Exercise	38.10	3,376	128,626	120,284	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '26	Sale	77.44	4,879	377,825	117,659	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 06 '26	Sale	76.95	1,739	133,816	119,162	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 06 '26	Sale	76.95	1,279	98,419	117,103	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '26	Sale	77.48	1,026	79,494	116,077	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 06 '26	Sale	76.95	54	4,155	6,902	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '26	Sale	77.48	52	4,029	6,850	Jan 08 05:20 PM
Golden Lee Scott	Officer	Jan 08 '26	Proposed Sale	76.45	866	66,205		Jan 08 04:45 PM
Pauwels Eric	Officer	Jan 08 '26	Proposed Sale	76.53	3,148	240,905		Jan 08 04:37 PM
Klein Matthew B.	Officer	Jan 08 '26	Proposed Sale	76.45	2,514	192,193		Jan 08 04:36 PM
Almstead Zheng Yang	Member of immediate family of	Jan 08 '26	Proposed Sale	76.45	59	4,510		Jan 08 04:29 PM
Almstead Neil Gregory	Officer	Jan 08 '26	Proposed Sale	76.45	881	67,352		Jan 08 04:27 PM
Pauwels Eric	Officer	Jan 08 '26	Proposed Sale	76.45	1,454	111,157		Jan 08 04:24 PM
Utter Christine Marie	Officer	Jan 08 '26	Proposed Sale	76.45	1,034	79,048		Jan 08 04:22 PM
Boulding Mark Elliott	Officer	Jan 08 '26	Proposed Sale	76.45	1,286	98,314		Jan 08 04:17 PM
Boulding Mark Elliott	Officer	Jan 08 '26	Proposed Sale	76.61	2,747	210,448		Jan 08 04:10 PM
Klein Matthew B.	Officer	Jan 07 '26	Proposed Sale	77.48	3,016	233,691		Jan 07 04:38 PM
Boulding Mark Elliott	Officer	Jan 07 '26	Proposed Sale	77.42	3,376	261,382		Jan 07 04:37 PM
Golden Lee Scott	Officer	Jan 07 '26	Proposed Sale	77.48	642	49,745		Jan 07 04:37 PM
Boulding Mark Elliott	Officer	Jan 07 '26	Proposed Sale	77.48	1,503	116,458		Jan 07 04:36 PM
Utter Christine Marie	Officer	Jan 07 '26	Proposed Sale	77.48	1,235	95,692		Jan 07 04:36 PM
Almstead Zheng Yang	Member of immediate family of	Jan 07 '26	Proposed Sale	77.48	52	4,029		Jan 07 04:21 PM
Pauwels Eric	Officer	Jan 07 '26	Proposed Sale	77.48	1,352	104,758		Jan 07 04:17 PM
Almstead Neil Gregory	Officer	Jan 07 '26	Proposed Sale	77.48	1,026	79,498		Jan 07 04:14 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 05 '26	Option Exercise	39.42	2,266	89,326	123,167	Jan 06 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 05 '26	Sale	75.55	2,266	171,192	120,901	Jan 06 05:20 PM
Reeve Emma	Director	Jan 05 '26	Option Exercise	46.54	734	34,160	11,400	Jan 06 05:20 PM
Reeve Emma	Director	Jan 05 '26	Sale	76.00	734	55,784	10,666	Jan 06 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Option Exercise	30.86	12,000	370,320	30,500	Jan 06 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Sale	76.35	12,000	916,200	18,500	Jan 06 05:20 PM
Klein Matthew B.	Officer	Jan 06 '26	Proposed Sale	76.95	5,149	396,203		Jan 06 04:46 PM
Utter Christine Marie	Officer	Jan 06 '26	Proposed Sale	76.95	1,381	106,265		Jan 06 04:42 PM
Golden Lee Scott	Officer	Jan 06 '26	Proposed Sale	76.95	1,340	103,110		Jan 06 04:33 PM
Boulding Mark Elliott	Officer	Jan 06 '26	Proposed Sale	76.95	1,739	133,812		Jan 06 04:25 PM
Gravier Pierre	Officer	Jan 06 '26	Proposed Sale	76.95	2,139	164,591		Jan 06 04:25 PM
Almstead Zheng Yang	Member of immediate family of	Jan 06 '26	Proposed Sale	76.95	54	4,155		Jan 06 04:24 PM
Pauwels Eric	Officer	Jan 06 '26	Proposed Sale	76.95	1,789	137,659		Jan 06 04:16 PM
Almstead Neil Gregory	Officer	Jan 06 '26	Proposed Sale	76.95	1,279	98,416		Jan 06 04:15 PM
Boulding Mark Elliott	Officer	Jan 05 '26	Proposed Sale	76.00	2,266	172,216		Jan 05 02:00 PM
Reeve Emma	Director	Jan 05 '26	Proposed Sale	76.00	734	55,784		Jan 05 11:02 AM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 30 '25	Sale	76.64	8,089	619,941	341,875	Jan 02 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Proposed Sale	76.35	12,000	916,200		Jan 02 12:37 PM
Klein Matthew B.	Officer	Dec 30 '25	Proposed Sale	76.64	8,089	619,922		Dec 30 03:09 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 19 '25	Option Exercise	65.15	20,508	1,336,186	90,178	Dec 23 05:15 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 19 '25	Sale	77.26	20,508	1,584,350	70,373	Dec 23 05:15 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 17 '25	Option Exercise	62.06	40,290	2,500,282	105,734	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 18 '25	Option Exercise	62.69	3,202	200,732	73,204	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 17 '25	Sale	75.43	40,290	3,038,924	70,373	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 18 '25	Sale	75.06	3,202	240,351	70,373	Dec 19 05:20 PM
Pauwels Eric	Officer	Dec 19 '25	Proposed Sale	77.26	20,508	1,584,388		Dec 19 04:18 PM
SCHMERTZLER MICHAEL	Director	Dec 16 '25	Option Exercise	30.86	24,000	740,640	155,266	Dec 18 05:20 PM
Pauwels Eric	Officer	Dec 18 '25	Proposed Sale	75.06	3,202	240,354		Dec 18 04:30 PM
Pauwels Eric	Officer	Dec 17 '25	Proposed Sale	75.42	40,290	3,038,756		Dec 17 04:30 PM
Reeve Emma	Director	Dec 03 '25	Option Exercise	46.54	733	34,114	7,399	Dec 05 05:20 PM
Reeve Emma	Director	Dec 03 '25	Sale	78.62	733	57,628	6,666	Dec 05 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 02 '25	Sale	79.07	3,428	271,052	349,964	Dec 03 05:20 PM
Reeve Emma	Director	Dec 03 '25	Proposed Sale	78.62	733	57,628		Dec 03 10:40 AM
Klein Matthew B.	Officer	Dec 02 '25	Proposed Sale	79.07	3,428	271,063		Dec 02 03:11 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 25 '25	Option Exercise	30.75	71,928	2,211,679	148,249	Nov 26 05:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 25 '25	Sale	83.44	71,928	6,001,932	100,625	Nov 26 05:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 24 '25	Option Exercise	30.23	35,572	1,075,296	121,831	Nov 26 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 24 '25	Sale	80.18	35,572	2,852,031	100,625	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 25 '25	Option Exercise	15.00	14,199	213,017	25,351	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 24 '25	Option Exercise	14.73	11,801	173,883	23,551	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 25 '25	Sale	83.55	14,199	1,186,282	17,451	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 24 '25	Sale	80.14	11,801	945,736	17,451	Nov 26 05:20 PM
Reeve Emma	Director	Nov 21 '25	Option Exercise	51.16	10,000	511,600	16,666	Nov 25 05:20 PM
Reeve Emma	Director	Nov 21 '25	Sale	79.50	10,000	795,000	6,666	Nov 25 05:20 PM
Almstead Neil Gregory	Officer	Nov 25 '25	Proposed Sale	83.44	71,928	6,001,523		Nov 25 05:18 PM
Jacobson Allan Steven	Director	Nov 25 '25	Proposed Sale	83.45	14,199	1,184,975		Nov 25 04:23 PM
Almstead Neil Gregory	Officer	Nov 24 '25	Proposed Sale	80.18	35,572	2,852,154		Nov 24 04:34 PM
Jacobson Allan Steven	Director	Nov 24 '25	Proposed Sale	80.14	11,801	945,753		Nov 24 04:29 PM
Reeve Emma	Director	Nov 21 '25	Proposed Sale	79.50	10,000	795,000		Nov 21 04:38 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Nov 17 '25	Option Exercise	25.69	2,812	72,240	106,713	Nov 19 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Nov 17 '25	Sale	75.99	2,812	213,687	103,901	Nov 19 05:20 PM
Boulding Mark Elliott	Officer	Nov 17 '25	Proposed Sale	75.01	2,812	210,928		Nov 17 10:06 AM
Reeve Emma	Director	Nov 12 '25	Option Exercise	46.54	7,333	341,278	13,999	Nov 14 05:20 PM
Reeve Emma	Director	Nov 12 '25	Sale	74.50	7,333	546,308	6,666	Nov 14 05:20 PM
Reeve Emma	Director	Nov 12 '25	Proposed Sale	74.50	7,333	546,308		Nov 12 11:58 AM

REPL

Replimune Group Inc

PTCT

PTC Therapeutics Inc

Upgrade your FINVIZ experience